First published online October 25, 2007
Stem Cells
Vol. 26 No.
1
January 2008, pp.
89
-98
doi:10.1634/stemcells.2007-0151; www.StemCells.com
© 2008 AlphaMed Press
Immunosuppression by Embryonic Stem Cells
Cody A. Kocha,b,
Pedro Geraldesa,b,
Jeffrey L. Platta,b,c,d
aTransplantation Biology Program and
Departments of bImmunology,
cSurgery, and
dPediatrics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Key Words. Stem cells • T cells • Dendritic cells
Correspondence: Jeffrey L. Platt, M.D., Transplantation Biology, 2-66 Medical Sciences Building, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA. Telephone: 507-538-0313; Fax: 507-284-4957; e-mail: platt.jeffrey{at}mayo.edu
Received February 28, 2007;
accepted for publication October 19, 2007.
First published online in STEM CELLS EXPRESS October 25, 2007.
Embryonic stem cells or their progeny inevitably differ genetically from those who might receive the cells as transplants. We tested the barriers to engraftment of embryonic stem cells and the mechanisms that determine those barriers. Using formation of teratomas as a measure of engraftment, we found that semiallogeneic and fully allogeneic embryonic stem cells engraft successfully in mice, provided a sufficient number of cells are delivered. Successfully engrafted cells did not generate immunological memory; unsuccessfully engrafted cells did. Embryonic stem cells reversibly, and in a dose-dependent manner, inhibited T-cell proliferation to various stimuli and the maturation of antigen-presenting cells induced by lipopolysaccharide. Inhibition of both was owed at least in part to production of transforming growth factor-β by the embryonic stem cells. Thus, murine embryonic stem cells exert "immunosuppression" locally, enabling engraftment across allogeneic barriers.
Disclosure of potential conflicts of interest is found at the end of this article.

Copyright © 2008 by AlphaMed Press.